leadf
logo-loader
viewJohnson & Johnson

Johnson & Johnson halts COVID-19 vaccine trials after unexplained illness

It is not clear whether the individual received a study treatment or a placebo

Johnson & Johnson - Johnson & Johnson halts COVID-19 vaccine trials after unexplained illness

Johnson & Johnson (NYSE:JNJ) announced it has paused dosing in all its COVID-19 vaccine candidate clinical trials after an unexplained illness in a study participant.

It is not clear whether the individual received a study treatment or a placebo.

READ: The runners in the COVID-19 vaccine race

The pharma giant stressed such adverse events are an expected part of any clinical study, especially large studies and there will be a careful review of all of the medical information before deciding whether to restart the study.

The phase III study of the jab is involving up to 60,000 participants in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the US.

“We must respect this participant’s privacy,” the US company noted, “we’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”

Quick facts: Johnson & Johnson

Price: 144.68 USD

NYSE:JNJ
Market: NYSE
Market Cap: $380.88 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Pan African Resources expands investor base with OTCQX upgrade, reveals...

Pan African Resources plc (LON:PAF) (OTCQX:PAFRY) CEO Cobus Loots tells Proactive that the South African-based gold-mining group upgraded to trade its shares on the OTCQX Best Market, because he feels the group has a lot to offer to US investors in terms of its profits, dividends, and growth,...

6 hours, 34 minutes ago

2 min read